Refining relabeling of pharmaceuticals

Patient safety is at the heart of drug development and licensing processes. But the duty of care does not stop at launch. Manufacturers must satisfy strict regulatory demands throughout a product’s lifecycle, including re-labeling.
1

4 steps corporates should take to prepare for LIBOR transition

It’s clear the LIBOR transition will have a huge impact on financial institutions. But corporates aren’t immune to the changes. Have you assessed how the LIBOR shift will impact your business? Find out what steps your business can take to stay ahead of the curve.
1

Implication of the U.S. Cloud Act on Privacy Aspects

In March 2018 the U.S. Congress enacted the U.S. Cloud Act. From an EU-perspective there is significant concern that U.S. authorities might undermine the EU GDPR requirements by compelling U.S. providers to allow access to certain types of data stored outside the U.S.
1

The Swiss trusts controversy

Use of trusts is widespread in English-speaking countries. Foreign trusts are both in demand and in use in Switzerland as well. On 13 March 2019, the National Council debated whether trusts should be included in the Swiss legal framework.
3

EBA Outsourcing Guidelines: Swiss banks also affected

The revised FINMA circular 2018/3 “Outsourcing - Banks” has now been in effect for nearly a year. Experience has shown that institutions are having a hard time particularly with the risk-oriented monitoring of their outsourcing providers (including any sub-contractors these may have hired).

Five building blocks to mitigating risk with an effective ICS

It’s been nearly nine months since the deadline to implement FINMA’s Circular 2017/1 “Corporate Governance – Banks”. And the odds are that you still have doubts about the effectiveness of the Internal Control System (ICS).